This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insulet Gains 62.9% in a Year: What's Driving the Stock?
by Zacks Equity Research
PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.
Revvity Stock Tumbles Despite Expanding Genomics England Alliance
by Zacks Equity Research
RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.
PODD Stock Gains Following the Launch of Omnipod 5 in Australia
by Zacks Equity Research
Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HealthEquity Stock Tumbles Despite the Launch of Assist Benefits Suite
by Zacks Equity Research
HQY launches Assist Suite to integrate personalized support, simplify benefits, and enhance engagement, aiming to reduce costs and improve outcomes.
Here's Why You Should Retain PacBio Stock in Your Portfolio Now
by Zacks Equity Research
PACB continues to deliver growth from its unique technologies amid macroeconomic concerns.
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5
by Zacks Equity Research
Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.
HQY Stock Falls as Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
HealthEquity surpasses fourth-quarter revenue expectations on robust HSA growth. It also provided fiscal 2026 guidance.
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
by Zacks Equity Research
NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology
by Zacks Equity Research
Tandem Diabetes launches Control-IQ+ technology commercially in the United States. Control-IQ+ is compatible with t:slim X2 insulin pump and Tandem Mobi System.
HYPR Stock Jumps on NVIDIA Partnership to Advance AI Neuroimaging
by Zacks Equity Research
Hyperfine partners with NVIDIA to integrate advanced AI into its Swoop MRI system, aiming to transform neuroimaging with faster and more accessible brain scan solutions.
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now
by Zacks Equity Research
SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months.
Will ISRG Stock Drop Continue After da Vinci 5 Recall?
by Zacks Equity Research
Intuitive Surgical faces a Class 2 recall for its da Vinci 5 system due to a pedal issue. Will this affect its 2025 rollout? Investors watch closely!
3 Reasons Growth Investors Will Love Masimo (MASI)
by Zacks Equity Research
Masimo (MASI) could produce exceptional returns because of its solid growth attributes.
Lifeward Stock Falls Despite FDA Clearance of ReWalk 7 Exoskeleton
by Zacks Equity Research
LFWD secures FDA clearance for its ReWalk 7 Exoskeleton, introducing enhanced features to empower individuals with spinal cord injury and expand mobility options.
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?
by Zacks Equity Research
ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.
Zacks.com featured highlights include Masimo, Robinhood Markets and Discover Financial Services
by Zacks Equity Research
Masimo, Robinhood Markets and Discover Financial Services are part of the Zacks Screen of the Week article.
Tempus Stock May Rise on the Acquisition of AI-Driven Deep 6 AI
by Zacks Equity Research
TEM announces the acquisition of Deep 6 AI, enhancing its AI-driven clinical trial matching capabilities to accelerate patient recruitment and revolutionize precision medicine.
Buy 3 Momentum Anomaly Stocks as Tariffs Take a Toll on Markets
by Supriyo Bose
MASI, HOOD and DFS are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
by Zacks Equity Research
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and WATCHMAN's performance.
Here's Why You Should Retain Glaukos Stock in Your Portfolio
by Zacks Equity Research
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Stryker Unveils Next-Generation Mako SmartRobotics but Stock Falls
by Zacks Equity Research
SYK unveils next-gen Mako SmartRobotics, revolutionizing hip, knee and spine surgeries with greater precision and first-to-market robotic hip revision technology.
Here's Why You Should Add Veeva Systems Stock to Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
TECH Stock Might Rise Following the Leo Shipping Announcement
by Zacks Equity Research
Bio-Techne begins to ship the Leo System - the next-generation high throughput simple western platform.
GEHC Stock May Gain as Genesis Portfolio Expands Cloud Offerings
by Zacks Equity Research
GE HealthCare unveils Genesis, a cloud-based imaging portfolio designed to enhance healthcare efficiency, streamline data access, and drive digital transformation.